If you have been reading about albumin conjugate and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-12-24. Numbers and descriptions here follow the published literature rather than marketing material.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
| Property | Value | Notes |
|---|---|---|
| Peptide class | Synthetic GHRH analogue | Built on a 29 residue sequence |
| Primary target | GHRH receptor (GHRHR) | Class B G protein coupled receptor |
| Unconjugated half life | Minutes | Limited by protease degradation |
| Key modification | Four residue substitutions | Positions 2, 8, 15 and 27 |
| Common synonym | Modified GRF(1-29) | Usually denotes the form without DAC |
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
== Release == Ninnu Kori was released on 7 July 2017. Later, a Hyderabad-Mumbai based production company, Aditya Movies bought the Hindi dubbing rights of the film. It is dubbed into Hindi as Aaj Ka Khiladi in 2020 which is to have a direct premiere on TV channel. Sony Networks bought the satellite rights of the Hindi dubbed version.
==== Australia ==== Harmala alkaloids are considered Schedule 9 prohibited substances under the Poisons Standard (October 2015). A Schedule 9 substance is a substance which may be abused or misused, the manufacture, possession, sale or use of which should be prohibited by law except when required for medical or scientific research, or for analytical, teaching or training purposes with approval of Commonwealth and/or State or Territory Health Authorities.
Valve has released two versions of a game controller aimed to be used for Steam games, the Steam Controller. The first model was released in November 2015, alongside the original Steam Machine concept, while the second was released in May 2026 ahead of Valve's dedciated Steam Machine model and Steam Frame. Among other features, both generations of the controller use two small trackpads with haptic feedback which can be used either as traditional controller actions like a joystick, but also like a computer mouse input to control many personal computer games that lack traditional controller support.
Sources: en.wikipedia.org
"Chorionic gonadotropin+beta [HCG];Csv";"Csv-Chorionic gonadotropin+beta chain; arb.stofk.(IS 75/589)";Clinical Biochemistry Laboratory "alpha-1-Fotoprotein;Csv";"Csv-alpha-1-Fotoprotein; arb.stofk.";Clinical Biochemistry Laboratory "Tick-borne encephalitis virus antibody; arb.k.(list; proc.);Csv";Tick-borne encephalitis virus antibody; Clinical Microbiology Laboratory "Cerebrospinal fluid group;Csv";"Csv-Nucleated cell type; count(list)";Clinical Biochemistry Laboratory "Erythrocytes;Csv";"Csv-Erythrocytes; count";Clinical Biochemistry Laboratory "Nucleated cells;Csv";"Csv-Nucleated cells; count";Clinical Biochemistry Laboratory "Nucleated cells;Csv";"Csv-Nucleated cells; count";Clinical Biochemistry Laboratory "Leukocytes(mononuclear);Lkc(Csv)";"Csv-Mononuclear cells; count";Clinical Biochemistry Laboratory "Leukocytes(mononuclear);Lkc(Csv)";"Csv-Leukocytes(mononuclear); count";Clinical Biochemistry Laboratory "Leukocytes (polynucleus);Lkc(Csv)";"Csv-Leukocytes(polynucleus); count";Clinical Biochemistry Laboratory "Leukocytes (polynuclear);Lkc(Csv)";"Csv-Polynuclear cells; count";Clinical Biochemistry Laboratory "Neurofilament light polypeptide;Csv";Csv(cell-free);Neuroimmunology Laboratory "Glucose;Csv";"Csv-Glucose; substance c.";Clinical Biochemistry Laboratory Alternatively formatted list: The following analyses (Normal Order Name; Designation in the laboratory; Laboratory) can be performed on cerebrospinal fluid (CSF) samples.
However, on tests done on Drosophila melanogaster, nongenotoxic TCAs (amitriptyline, maprotiline, nortriptyline, and protriptyline), and genotoxic TCAs (amoxapine, clomipramine, desipramine, doxepin, imipramine, and trimipramine) were identified.
== Predictive genetic testing == Due to the high cost of immunotherapy and the reluctance of insurers to pre-authorize treatment, various genetic and molecular tests have been developed to predict therapeutic response. Three major biomarkers are currently FDA-approved and widely used in clinical practice: (1) programmed death-ligand 1 (PD-L1) expression, (2) microsatellite instability (MSI) or mismatch repair deficiency (dMMR), and (3) tumor mutational burden (TMB). PD-L1 expression, detected via immunohistochemistry, may indicate which tumors are more likely to respond to immune checkpoint inhibitors by revealing the presence of proteins that help cancer cells evade immune surveillance. However, its predictive value is limited by variability in expression across tumor types, locations, and testing platforms. MSI and dMMR, identified through molecular or immunohistochemical testing, indicate a deficiency in DNA repair mechanisms and are associated with high mutation rates that may increase tumor immunogenicity. These biomarkers have been approved to guide the use of checkpoint inhibitors in several cancer types. TMB, measured by next-generation sequencing, quantifies the total number of somatic mutations in a tumor genome. High TMB has been associated with improved responses to immunotherapy, although its clinical utility remains controversial and context-dependent. As of 2023, reliance on TMB as a selection criterion for immunotherapy was still debated in the scientific community.
Sources: en.wikipedia.org
The names are often used interchangeably in casual writing, but they are not strictly identical. Modified GRF(1-29) refers to the unconjugated analogue carrying only the four substitutions. The version sold as CJC-1295 with DAC includes the albumin binding linker and clears much more slowly.
DAC stands for drug affinity complex, a term describing the maleimidopropionic acid linker. This group forms a covalent bond with the cysteine residue on serum albumin after administration. The resulting adduct is what extends the circulating half life from minutes to days.
No. It is entirely synthetic and does not correspond to any known endogenous peptide. The design starts from human growth hormone releasing hormone and introduces deliberate substitutions. Any biological effect comes from mimicking the natural hormone at its receptor.
No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.